Eli Lilly and

LLY · NYSE · USD

$1,142.85−0.61%−$7.00

Close · October 2, 2026

At a glance

Revenue growth: +44.70%; 2025 vs 2024
Net income growth: +94.90%; 2025 vs 2024
Net margin: 31.7%; 2024: 23.5%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

Income statement · Annual
Item	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016
Total revenue	65,179	45,043	34,124	28,541	28,318	24,540	22,320	21,493	19,974	21,222
Cost of revenue	11,052	8,418	7,082	6,630	6,973	5,483	4,721	4,682	4,448	5,710
Gross profit	54,127	36,625	27,042	21,912	21,345	19,057	17,598	16,812	15,526	15,512
Selling, general and administrative	11,094	8,594	7,404	6,068	6,142	5,869	6,004	5,735	5,733	6,330
Research and development	13,337	10,991	9,313	7,191	6,931	5,976	5,595	5,051	5,096	5,310
Operating income	29,696	17,040	10,325	8,653	8,273	7,211	5,999	6,026	4,697	3,871
EBIT	29,696	17,040	10,325	8,653	8,273	7,211	5,999	6,026	4,697	3,871
EBITDA	31,693	18,807	11,852	10,176	9,820	8,535	7,232	7,635	6,264	5,271
Interest expense	—	781	486	332	340	360	401	243	225	185
Pre-tax income	25,731	12,680	6,554	6,806	6,156	7,230	5,266	3,680	2,305	3,374
Income tax	5,091	2,090	1,314	562	574	1,036	628	530	2,391	636
Net income	20,640	10,590	5,240	6,245	5,582	6,194	8,318	3,232	-204	2,738
Net income to common shareholders	20,640	10,590	5,240	6,245	5,582	6,194	4,638	3,151	-86.4	2,738
Basic EPS	23.00	11.76	5.82	6.93	6.15	6.82	4.98	3.07	-0.08	2.59
Diluted EPS	22.95	11.71	5.80	6.90	6.12	6.79	4.96	3.05	-0.08	2.58
Average shares (basic)	897	901	900	902	907	908	931	1,028	1,052	1,058
Average shares (diluted)	899	904	903	905	912	913	936	1,034	1,052	1,062
Dividend per share	6.00	5.20	4.52	3.92	3.40	2.96	2.58	2.25	2.08	2.04